Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Last trade$0.2138
Day change-$0.0022 (-1.02%)
Day range$0.203 – $0.218
Volume2,008,614
Market cap$16M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$15.91M
Price / earnings
—
Price / book
0.46×
Price / sales
—
EV / sales
—
EV / EBITDA
0.1×
Profitability
Earnings per share
-$1.44
Return on assets
-121.5%
Return on equity
-300.38%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.76×
Current ratio
1.89×
Quick ratio
1.89×
Cash ratio
1.18×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$87.95M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ABOS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.7M
$4.75M
$4.67M
$4.67M
$4.55M
$4.63M
$5.1M
$5.03M
Research and development
$21.11M
$27.81M
$16.48M
$20.53M
$21.97M
$37.13M
$25.27M
$34.57M
Total operating expenses
$25.81M
$32.56M
$21.15M
$25.2M
$26.51M
$41.75M
$30.37M
$39.6M
Operating income
-$25.81M
-$32.56M
-$21.15M
-$25.2M
-$26.51M
-$41.75M
-$30.37M
-$39.6M
Interest expense
-$999K
-$1.09M
-$1.07M
-$1.09M
-$1.07M
-$1.05M
-$1.02M
-$1.04M
Income before taxes
-$25.37M
-$32.72M
-$20.74M
-$25.14M
-$26.45M
-$40.95M
-$28.8M
-$37.15M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$25.37M
-$32.72M
-$20.74M
-$25.14M
-$26.45M
-$40.95M
-$28.8M
-$37.15M
Net income attributable to common shareholders
-$25.37M
-$32.72M
-$20.74M
-$25.14M
-$26.45M
-$40.95M
-$28.8M
-$37.15M
EBITDA
-$25.8M
-$32.55M
-$21.14M
-$25.19M
-$26.5M
-$41.73M
-$30.36M
-$39.58M
Basic earnings per share
-$0.35
-$0.45
-$0.33
-$0.41
-$0.44
-$0.68
-$0.48
-$0.62
Diluted earnings per share
-$0.35
-$0.45
-$0.33
-$0.41
-$0.44
-$0.68
-$0.48
-$0.62
Recent news
Company coverage with links to the original publishers.
Acumen Pharmaceuticals expects to report Phase II trial results for its Alzheimer's drug candidate sabirnetug in November 2026, testing whether targeting amyloid-beta oligomers slows cognitive decline. The company has $79 million in cash reserves supporting operations into early 2027, and its enhanced brain delivery platform showed a 40-fold increase in brain exposure in preclinical studies, positioning it for potential regulatory filings in mid-2027.
Acumen Pharmaceuticals reported Q3 2026 results with a net loss of $25.4 million and cash reserves of $78.6 million expected to support operations into early 2027. The company is preparing for November 2026 topline results from its Phase 2 ALTITUDE-AD trial testing sabirnetug for early Alzheimer's disease, with 542 participants enrolled. Management expects a 30% slowing of cognitive decline on the iADRS scale as the clinical success benchmark and anticipates low double-digit ARIA-E safety rates. The company is also advancing its Enhanced Brain Delivery program toward an IND filing in mid-2027.
Acumen Pharmaceuticals announced a virtual Investor Day scheduled for September 16, 2026, to discuss its clinical-stage pipeline. The company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease treatment, with Phase 2 ALTITUDE-AD trial results expected in late 2026. Acumen is also exploring subcutaneous formulations and collaborating with JCR Pharmaceuticals on enhanced brain delivery technologies.
Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.
Acumen Pharmaceuticals reported Q1 2026 financial results with cash reserves of $128.4 million. The company expects topline results from its Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in late 2026, and plans to file an IND for its lead EBD program candidate in mid-2027. R&D expenses decreased to $16.5 million from $25.3 million year-over-year due to reduced manufacturing and CRO costs following ALTITUDE-AD enrollment completion.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.